Company Overview
Snapshot
Founded in May 2018 by Miki Olshansky and Stav Zeldis, ELGAN Pharma operates with 11–50 employees. The company has raised $7.5 million across three funding rounds from two investors. In June 2025, ELGAN Pharma and Chiesi Group announced the dosing of the first infants in a Phase 3 study for ELGN-2112, a treatment for intestinal malabsorption in preterm infants.
Business overview
ELGAN Pharma is a clinical-stage biotechnology company focused on neonatology, developing tailored therapies for medical problems and developmental difficulties in premature babies. The company's core products include ELGN-GI, which promotes faster intestinal maturation to reduce reliance on parenteral nutrition, and ELGN-EYE, a local drug designed to prevent vision impairment from retinopathy of prematurity (ROP). ELGAN Pharma serves the healthcare and life sciences sectors, specifically targeting the needs of preterm infants and healthcare providers.
Strategic signal
In June 2025, ELGAN Pharma, in collaboration with Chiesi Group, began dosing the first infants in a Phase 3 clinical trial for ELGN-2112, a treatment for intestinal malabsorption in preterm infants. This milestone signifies significant progress in addressing a critical unmet medical need in neonatal care, indicating strong clinical validation and a clear path toward potential market entry for a high-impact therapeutic solution.
Log in to access full profile ›Company Intelligence Q&A
- What is ELGAN Pharma's primary focus?
- ELGAN Pharma is a clinical-stage biotechnology company specializing in neonatology, developing safe and tailored therapies for medical issues and developmental challenges in premature infants.
- What is the status of ELGAN Pharma's ELGN-GI product?
- ELGN-GI, designed to promote faster intestinal maturation in infants, has completed several clinical trials, including a successful Phase 3 study, and is currently initiating a second Phase 2 study.
- What is the purpose of ELGAN Pharma's ELGN-EYE product?
- ELGN-EYE is a local drug aimed at preventing vision impairment due to retinopathy of prematurity (ROP), a leading cause of blindness in children worldwide. A Phase 1 study for ELGN-EYE was successfully concluded, and a Phase 2 is currently launching.
- Has ELGAN Pharma received any grants recently?
- In July 2023, ELGAN Pharma was awarded a $2.5 million grant by the European Innovation Council (EIC) to support a clinical study for its oral formula treating intestinal malabsorption in preterm infants.
- What was the outcome of the partnership between ELGAN Pharma and Chiesi Group?
- In June 2025, ELGAN Pharma and Chiesi Group announced the dosing of the first participating infants in the FIT-PIV Phase 3 clinical study for ELGN-2112, a treatment for intestinal malabsorption in preterm infants.